The Scientific Basis of Early Detection of Epithelial Ovarian Cancer: The National Ovarian Cancer Early Detection Program (Nocedp)

  • David A. Fishman
  • Kenny Bozorgi
Part of the Cancer Treatment and Research book series (CTAR, volume 107)

Abstract

In the United States ovarian cancer is the leading cause of death from gynecologic malignancies and is the fifth most common female malignancy. Each year approximately 24,000 women will be newly diagnosed with ovarian cancer and 14,000 will die from this disease. In industrialized countries ovarian cancer accounts for more deaths than uterine and cervical cancer combined. The incidence of ovarian cancer has been steadily increasing over the past ten years, now with an overall lifetime risk of 1.8%. Ovarian cancer rapidly increases in occurrence after age 40 with the mean age of occurrence at 60 (1). Epidemiologic factors associated with ovarian cancer include nulliparity, a personal history of colon or breast cancer, an affected first degree relative with ovarian cancer, a family history of a recognized inherited malignancy syndrome, as well as a history of prolonged use of fertility drugs (2). Due to our current inability in detecting cancer confined to the ovary (stage I disease), the majority of women (75%) are diagnosed with tumor spread throughout the abdominal cavity (stage III or IV). This extensive spread of ovarian carcinoma often is associated with subtle symptoms such as bloating, early satiety, abdominal discomfort, or changes in bowel or bladder habits; vague symptoms that may often be dismissed by patient and/or healthcare provider or simply misdiagnosed. It is the anatomic location of the ovaries that contributes to our inability to detect early stage ovarian carcinoma. Despite significant improvements in surgical techniques, critical care and new chemotherapeutic regimens, the overall 5-year survival for women with stage III/IV epithelial ovarian carcinoma has remained constant (12 – 20%) over the past 30 years. Conversely, those patients diagnosed with stage I disease usually only require surgical intervention without chemotherapy and have an overall 5-year survival approximating 90%. Therefore the early detection of early stage epithelial ovarian cancer is essential in curbing the morbidity and mortality from this disease.

Keywords

Ovarian Cancer Human Epidermal Growth Factor Receptor Ovarian Carcinoma Epithelial Ovarian Cancer Ovarian Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landis, SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. CA-A Cancer J Clin 1998; 48: 6–30.CrossRefGoogle Scholar
  2. 2.
    Friedlander ML. Prognostic Factors in Ovarian Cancer. Seminars in Oncology 1998; 25: 305 314.Google Scholar
  3. 3.
    Cronin KA, Weed DL, Connor RI, Prorok PC. Case-Control Studies of Cancer Screening: Theory and Practice. J Natl Can Inst 1998; 90: 498–504.CrossRefGoogle Scholar
  4. 4.
    Kohn E, Liotta L. Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention Perspectives. Cancer Research 1995; 55: 1856–1862.PubMedGoogle Scholar
  5. 5.
    Link, Jr CJ, Kohn E, Reed E. The Relationship between Borderline Ovarian Tumors and Epithelial Ovarian Carcinoma: Epidemiologic, Pathologic, and Molecular Aspects-Review. Gyne Onc 1996; 60: 347–354.CrossRefGoogle Scholar
  6. 6.
    Katso RMT, Manek S, O’Bryne K, Playford MP, LeMeuth V, Ganesan TS Molecular approaches to diagnosis and management of ovarian cancer. Cancer and Metastasis Reviews 16: 81–107, 1997.PubMedCrossRefGoogle Scholar
  7. 7.
    Fishman DA, Kearns A, Chilukuri K, Bafetti LM, O’Toole, EA, Georgacopoulos J, Ravosa MJ, and Stack MS. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by a2b1integrin mediated interaction with type I collagen. Inv Mets 1998; 18: 15–26.Google Scholar
  8. 8.
    Fishman DA and Stack MS. The role of tumor cell adhesion in ovarian metastasis. CME Gynecol Oncol 1999; 4: 201–204.Google Scholar
  9. 9.
    McCawley LJ, O’Brien P, Hudson LG. Epidermal Growth Factor (EGF) -and Scatter Factor/Hepatocyte Growth Factor (SF/HCF)- Mediated Keratinocyte Migration Is Coincident With Induction of Matrix Metalloproteinase (MMP)-9. J of Cellular Physiology 1998; 176: 255–265.CrossRefGoogle Scholar
  10. 10.
    Wikstrand CJ, Bigner DD Prognostic Applications of the Epidermal Growth Factor Receptor and Its Ligand, Transforming Growth Factor-«. J Nat! Can Inst 1998; 90: 11–13.Google Scholar
  11. 1.
    I. Niikura H, Sasano H, Sato S. Yajima A. Expression of Epidermal Growth Factor-Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors. lnt J Gyne Pathol 1997; 16: 60–68.Google Scholar
  12. 12.
    Xu Y, Fang XJ, Fumi T, Sasagawa T, Pustilnik T, Lu Y, Shen Z, Wiener JR, Shayesteh L, Gray JW, Bast RC, Mills GB. “Regulation of growth of ovarian cancer cells by phospholipid growth factors”. In Ovarian Cancer 5, Sharp, F., Blackett, T., Berek, J. and Bast, RC., eds. Oxford UK., ISIS Medical Media, 1998.Google Scholar
  13. 13.
    Friedlander ML. Prognostic Factors. Ovarian Cancer Seminars in Oncology 1998; 25: 305–314.Google Scholar
  14. 14.
    Berchuck A. Biomarkers in the Ovary. J Cellular Biochem 1995; 23: 223–226.CrossRefGoogle Scholar
  15. 15.
    Berek JS, Bast, Jr RC. Ovarian Cancer Screening. Cancer 1995; 76: 2092–2096.PubMedCrossRefGoogle Scholar
  16. 16.
    Cronin KA, Weed DL, Connor RJ, Prorok PC. Case-Control Studies of Cancer Screening: Theory and Practice. J Natl Can Inst 1998; 90: 7498–504.Google Scholar
  17. 17.
    Schwartz PE, Chambers JT, Taylor KJ. Early Detection and Screening for Ovarian Cancer. J Cellular Biochem 1995; 23: 233–237.CrossRefGoogle Scholar
  18. 18.
    Rosenthal A, Jacobs I. Ovarian Cancer Screening. Seminars in Oncology 1998; 25: 315–325.PubMedGoogle Scholar
  19. 19.
    Abrahamson JA, Moslehi R, Vesprini D, Karlan B, Fishman D, Smotkin D, Ben David Y, Biran H, Fields A, Brunet JS, Narod S. No Association of the 11307K APC Allele with Ovarian Cancer Risk in Ashkenazi Jews. Cancer Research 1998; 58: 2919–2922.PubMedGoogle Scholar
  20. 20.
    Randall TC, Rubin SC Assessing A Patient’s Risk For Hereditray Ovarian Cancer. OBG Management 1998; 37–46.Google Scholar
  21. 21.
    Fishman DA. The present and future of biomarkers for the early detection of epithelial ovarian cancer. CME Gynecol Oncol 1999; 4: 33–36.Google Scholar
  22. 22.
    Bast, R.C. Jr. and Mills, G.B. “Alterations in Oncogenes, Tumor Suppressor genes, and Growth Factors Associated with Epithelial Ovarian Cancers.” In Ovarian Cancer Methods and Protocols, I.M.S. Bartlett, ed., Humana Press, 2000.Google Scholar
  23. 23.
    Slamon, D.J., Godolphin, W., Jones, L.A., Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.PubMedCrossRefGoogle Scholar
  24. 24.
    Berchuck, A., Kamel, A., Whitaker, R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087–4091.PubMedGoogle Scholar
  25. 25.
    Xu F.J., Yu, Y.H., Boyer, C.M., et al. Stimulation or inhibition of ovarian cancer cell cell proliferation by heregulin is dependent on the ratio of HER2 to HER3 or HER4 expression. Proc Amer. Assoc. Cancer Res. 1996; 37: 191.Google Scholar
  26. 26.
    Xu, F.J., Stack, S., Boyer, C., et al. Heregulin and agonistic anti-p185c-erbB2 antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress anti-pl85c-erbB2: Increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3: 1629–1634.PubMedGoogle Scholar
  27. 27.
    Zhou, B.P., Hu, M.C., Miller, S.A., et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000; 275: 8027–8031.PubMedCrossRefGoogle Scholar
  28. 28.
    Baselga, J., Tripathy, D., Mendelsohn., et al. Phase II study of weekly intravenous recombinant humanized ant-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14: 737–744.PubMedGoogle Scholar
  29. 29.
    Slamon, D., Leyland-Jones, B., Shak, S., et al. Addition of herceptin (humanized anti-Her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase II trial. Proc Amer Soc Clin Oncol 1998; 17: 98.Google Scholar
  30. 30.
    Ueno, N.T., Hung, M.C., and Zhang, S. Phase I ElA gene therapy in patients with advanced breast and ovarian cancers. Proc Amer Soc Clin Oncol 1998; 17: 432a.Google Scholar
  31. 31.
    Kacinski B.M., Carter D, Mittal K, et al. Ovarian adenocarcinomas express fins-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990; 137: 135–147.PubMedGoogle Scholar
  32. 32.
    Chambers S.K., Ivins C.M., and Carcangiu M.L. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1. Int J Cancer 1997; 74: 571–575.PubMedCrossRefGoogle Scholar
  33. 33.
    Shayesteh L, Lu Y, Kuo W.L., Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99–102.PubMedCrossRefGoogle Scholar
  34. 34.
    Hu L, Zaloudek, Mills G.B., Gray J, and Jaffe R.B. In vivo and in vitro carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res 2000; 6: 880–886.Google Scholar
  35. 35.
    Liu A.X., Testa J.R., Hamilton T.C., Jove R, Nicosia S.V, and Cheng J.Q. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998; 58: 2973–2977.PubMedGoogle Scholar
  36. 36.
    Bellacosa A, de Feo D, Godwin A.K., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280–285.PubMedCrossRefGoogle Scholar
  37. 37.
    Yuan Z.Q., Sun M,Feldman R.I., Wang G, Ma X, Jiang C, coppola D, Nicosia S.V., and Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324–2330.PubMedCrossRefGoogle Scholar
  38. 38.
    Page C, Lin H.J, Jin Y, Castle VP, Nunez G, Huang M, and Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000; 20: 407–416.PubMedGoogle Scholar
  39. 39.
    Marks J.R., Davidoff A.M., Kerns B.J.M, et al. Overexpression and mutation of p53in epithelial ovarian cancer. Cancer Res 1991; 5: 2979–2984.Google Scholar
  40. 40.
    Sakai K, Kaku T, Kamura T, Kinukawa N, Amada S, Shigematsu T, Kobayashi H, Ariyoshi K, and Nakano H. Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. Gyn Oncol 1999; 72: 360–366.CrossRefGoogle Scholar
  41. 41.
    Sood A.K., Sorosky J.I., Dolan M, Anderson, and Buller R. E. Distant metastases in ovarian caner: association with p53 mutations. Clin Cancer Res 1999; 5: 2485–2490.Google Scholar
  42. 42.
    Schildkraut J, Bastos E, and Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Nat Cancer Inst 1997; 89: 932–938.PubMedCrossRefGoogle Scholar
  43. 43.
    Obata K, Morland S.J., Watson R.H., Hitchcock A, Chenevix-Trench G, Thomas E.J., and Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095–2097.PubMedGoogle Scholar
  44. 44.
    Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y and Nakamura Y. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 1999; 59: 6063–6067.PubMedGoogle Scholar
  45. 45.
    Gallion, HH and Bast, RC, Jr. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res 1993; 53: 3839–3842.PubMedGoogle Scholar
  46. 46.
    Xu Y, Fang XJ, Casey G, and Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309: 933–940.PubMedGoogle Scholar
  47. 47.
    Xu Y, Shen Z, Wiper D, Wu M, Morton R, Elson P, Kennedy AW, Belinson J, Markman M, and Casey G. Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers. JAMA 1998; 280: 719–723.PubMedCrossRefGoogle Scholar
  48. 48.
    Watson SP, McConnell RT, Lapetina EG. Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role of lysophosphatidic acid. Biochem. J 1985; 232: 61–66.PubMedGoogle Scholar
  49. 49.
    Tigyi G, Henschen A, Miledi R. A factor that activates oscillatory chloride currents in Xenopus oocytes copurifies with a subfraction of serum albumin. J Biol Chem 1991; 266: 20602–20609.PubMedGoogle Scholar
  50. 50.
    Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activates membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 1992; 267: 21360–21367.PubMedGoogle Scholar
  51. 51.
    Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677–680.PubMedGoogle Scholar
  52. 52.
    Tokumura A, limon M, Niishioka Y, kitahara M, Sakashita M, Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol 1994; 267: C204–210.PubMedGoogle Scholar
  53. 53.
    Siuzdak G. in Mass Spectrometry for Biotechnology, San Diego, Academic Press, 1996Google Scholar
  54. 54.
    Weintraub ST, Pinckard RN, Hail M, Electrospray ionization for analysis of platelet-activating factor. Rapid Commun Mass Spectrom 1991; 5: 309–11.PubMedCrossRefGoogle Scholar
  55. 55.
    Kerwin IL, Tuininga AR, Ericsson LH. Identification of molecular species of glycerophospholipids and sphingomyelin using electrospray mass spectrometry. J Lipid Res 1994; 35: 1102–1114.PubMedGoogle Scholar
  56. 56.
    Han X, Gubitosi-Klug RA, Collins BJ, Gross RW. Alterations in individual molecular species of human platelet phospholipids during thrombin stimulation: electrospray ionization mass spectrometry-facilitated identification of the boundary conditions for the magnitude and selectivity of thrombin-induced platelet phospholipid hydrolysis. Biochemistry 1996; 35: 5822–5832.PubMedCrossRefGoogle Scholar
  57. 57.
    Hoischen C, Ihn W, Gura K, Gumpert J. Structural characterization of molecular phospholipid species in cytoplasmic membranes of the cell wall-less Streptomyces hygroscopicus L form by use of electrospray ionization coupled with collision-induced dissociation mass spectrometry. J Bacteriol 1997; 179: 3437–3442.PubMedGoogle Scholar
  58. 58.
    Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA, Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272: 13597–13607.PubMedCrossRefGoogle Scholar
  59. 59.
    Ramanadham S, Hsu FF, Bohrer A, Nowatzke W, Ma Z, Turk J. Electrospray ionization mass spectrometric analyses of phospholipids from rat and human pancreatic islets and subcellular membranes: comparison to other tissues and implications for membrane fusion in insulin exocytosis. Biochemistry 1998; 37: 4553–4567.PubMedCrossRefGoogle Scholar
  60. 60.
    Karlsson AA, Michelsen P, Odham G, Molecular species of sphingomyelin: determination by high-performance liquid chromatography mass spectrometry with electrospray and high-performance liquid chromatography/tandem mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 1998; 33: 1192–1198.PubMedCrossRefGoogle Scholar
  61. 61.
    Byrdwell WC, Dual parallel mass spectrometers for analysis of sphingolipid, glycerophospholipid and plasmalogen molecular species. Rapid Commun Mass Spectrom 1998; 12: 256–272.PubMedCrossRefGoogle Scholar
  62. 62.
    Hsu FF, Bohrer A, Turk J, Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry. J Am Soc Mass Spectrom 1998; 9: 516–526.PubMedCrossRefGoogle Scholar
  63. 63.
    Xu Y, Gaudette DC, Boynton J, Frankel A, Fang X-J, Sharma A, Hurteau J, Casey G, Goodbody AE, Mellors A, Holub BJ, Mills G. Characterization of an ovarian cancer activating factor(OCAF) in ascites from ovarian cancer patients. Clinical Cancer Res. 1995; 1: 1223–1232.Google Scholar
  64. 64.
    Katso RMT, Manek S, Bryne K, Playford MP, LeMeuth V, Ganesan TS. Molecular approaches to diagnosis and management of ovarian cancer, Cancer and Metastasis Reviews 1997; 16: 81–107.PubMedCrossRefGoogle Scholar
  65. 65.
    Liotta, L.A., Rao, C.N., and Wewer, U.M. Biochemical interactions of tumor cells with the basement membrane. Ann. Rev. Biochem. 1986; 55: 1037–1057.PubMedCrossRefGoogle Scholar
  66. 66.
    Sawada, M., Shii, J., Akedo, H., and Tanizawa, O. An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest 1994; 70: 333–338.PubMedGoogle Scholar
  67. 67.
    Niedbala, M.J., Crickard, K, and Bemacki, R.J. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. Exp Cell Res 1985; 160: 499–513.PubMedCrossRefGoogle Scholar
  68. 68.
    Auersperg, N., Maclaren, I.A., and Kruk, P.A. Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. Biol Reprod 1991; 44: 717–724.PubMedCrossRefGoogle Scholar
  69. 69.
    Cannistra, S.A., Ottensmeier, C., Niloff, J., Orta, B., and DiCarlo, J. Expression and function of alphal and alphavbeta3 integrins in ovarian cancer. Gyn Oncol 1997; 58: 216–225.CrossRefGoogle Scholar
  70. 70.
    Hynes, R.O. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992; 69: 11–25.PubMedCrossRefGoogle Scholar
  71. 71.
    Huttenlocher, A., Sandborg, R.R., and Horwitz, A.F. Adhesion in cell migration. Current Opinion Cell Biol 1995; 7: 697–706.PubMedCrossRefGoogle Scholar
  72. 72.
    Fishman, D.A., Bafetti., L.M., and Stack, M.S. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1997; 16: 150–159.Google Scholar
  73. 73.
    Moser, T.L., Pizzo, S.V., Bafetti, L.M., Fishman, D.A., and Stack, M.S. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2 betal integrin. Int J Cancer 1996; 67: 695–701.PubMedCrossRefGoogle Scholar
  74. 74.
    Fishman, D.A., Chilukuri, K., and Stack, M.S. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity. Gyn Oncol 1997; 67: 193–199.CrossRefGoogle Scholar
  75. 75.
    Fishman, D.A., Bafetti, L.M., Banionis, S., Keams, A.S., Chilukuri, K., and Stack, M.S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997; 80: 1457–1463PubMedCrossRefGoogle Scholar
  76. 76.
    Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian cancer. Int J Oncol 1998; 12: 569–76.PubMedGoogle Scholar
  77. 77.
    Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, and Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer; 80: 1457–63, 1997.PubMedCrossRefGoogle Scholar
  78. 78.
    Gilles, C., Polette, M., Seiki, M., Birembaut, P., and Thompson, E.W. Implication of collagen type 1-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997; 76: 651–660.PubMedGoogle Scholar
  79. 79.
    Stack, M.S., Gray, R.D., and Pizzo, S.V. Modulation of murine BI6F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res 1993; 53: 1998–2004.PubMedGoogle Scholar
  80. 80.
    Sier CFM, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, and Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843–49.PubMedGoogle Scholar
  81. 81.
    Duggan BD, Minghong W, Yu MC, Roman LD, Muderspach LI, Delgadillo E, Wei-Zhi L, Martin SE, Dubeau L. Detection of Ovarian Cancer Cells: Comparison of a Telomerase Assay and Cytologic Examination J Nat Can Inst 1998; 90: 238–242.CrossRefGoogle Scholar
  82. 82.
    Kim NW, Wu F Advances in quantification and characterization of telomerase activity by telomeric repeat amplification protocol (TRAP), Nucleic Acids Research 1997; 25: 2595–2597.PubMedCrossRefGoogle Scholar
  83. 83.
    Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF. Telomerase Expression in Respiratory Epithelium during the Multistage Pathogenesis of Lung Carcinomas, Cancer Res 1997; 57: 2373–2377.PubMedGoogle Scholar
  84. 84.
    Hirano Y, Fujita K, Suzuki K, Ushiyama T, Ohtawara Y, Tsuda F. Telomerase Activity as an Indicator of Potentially Malignant Adrenal Tumors, Cancer 1998; 83: 772–776.PubMedCrossRefGoogle Scholar
  85. 85.
    Bryan TM, Englezou A, Dalla-Pozza L, Dunham M, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell tumors. Nature Medicine 1007; 3: 11.Google Scholar
  86. 86.
    Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer Proc Natl Acad Sci 1994; 91: 9871–9875.CrossRefGoogle Scholar
  87. 87.
    Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL and Bast RCJ. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991; 164: 669–674.PubMedGoogle Scholar
  88. 88.
    Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull 1991; 47: 87–98.PubMedGoogle Scholar
  89. 89.
    Salomon DS, Brandt R, Ciardiello F and Normanno N Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Rev. Oncol/Hematol 1995; 19: 183–232.CrossRefGoogle Scholar
  90. 90.
    Scambia, G., Panici P.B., Battaglia F., Ferrandina G., Baiocchi G., Greggi S., Vincenzo R.D. and Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992; 10: 529–535.PubMedGoogle Scholar
  91. 91.
    Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC and Maihle NJ. Serum sErbB I and EGF levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prey 1998.Google Scholar
  92. 92.
    Haley J, Whittle N, Bennett P, Kinchington D, Ullrich A and Waterfield M. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987; 1: 375–396.PubMedGoogle Scholar
  93. 93.
    Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, Venna IM, Gill GN and Rosenfeld MG Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984; 224: 843–848.PubMedCrossRefGoogle Scholar
  94. 94.
    Yarden Y and Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987; 26: 1443–1551.PubMedCrossRefGoogle Scholar
  95. 95.
    Spaargaren, M., Defize L.H., Boonstra J. and de Laat S.W. Antibody-induced dimerization activates the epidermal growth factor receptor tyrosine kinase. J Biol Chem 1991; 266: 1733–1739.PubMedGoogle Scholar
  96. 96.
    Spivak-Kroizman, T., Rotin D., Pinchasi D., Ullrich A., Schlessinger J. and Lax I. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory respnses. J Biol Chem 1992; 267: 8056–8063.PubMedGoogle Scholar
  97. 97.
    Lax, I., Johnson A., Howk R., Sap J., Bellot F., Winkler M., Ullrich A., Vennstrom B., Schlessinger J. and Givol D. Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor-alpha. Mol Cell Biol 1988; 8: 1970–1978.PubMedGoogle Scholar
  98. 98.
    Di Fiore, P.P., Pierce J.H., Fleming T.P., Hazan R., Ullrich A., King C.R., Schlessinger J. and Aaronson S.A. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987; 51: 1063–1070.PubMedCrossRefGoogle Scholar
  99. 99.
    Leitzel, K., Teramoto Y., Konrad K., Chinchilli V.M., Volas G., Grossberg H., Harvey H., Demers L. and Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129–1135.PubMedGoogle Scholar
  100. 100.
    Baron, A.T., Lafky J.M., Connolly D.C., Peoples J.J., O’Kane D.J., Suman V.J., Boardman C.H., Podratz K.C. and Maihle N.J. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J. Immunol. Methods 1998.Google Scholar
  101. 101.
    Ozols RF, Rubin SC, Dembo Al, and Robboy SJ. “Epithelial Ovarian Cancer.” in Principles and Practice of Gynecologic Oncology, Hoskins WJ, Perez CA, and Young RC, eds, Lippincott Co, 1997.Google Scholar
  102. 102.
    Gusberg SB, Deligdisch L. Ovarian Dysplasia- A Study of Identical Twins. Cancer 1984; 54: 1–4.PubMedCrossRefGoogle Scholar
  103. 103.
    Deligdisch L, Gil J. Characterization of Ovarian Dysplasia by Interactive Morphometry. Cancer 1989; 63: 748–755.PubMedCrossRefGoogle Scholar
  104. 104.
    Deligdisch L, Gil J. Interactive Morphometric Procedures and Statistical Analysis in the Diagnosis of Ovarian Dysplasia and Carcinoma. Path Res Pract 1989; 185: 680–685.PubMedCrossRefGoogle Scholar
  105. 105.
    Plaxe SC, Deligdisch L, Dotting PR, Cohen CJ. Ovarian Intraepithelial Neoplasia Demonstrated in Patients with Stage I Ovarian Carcinoma, Gyn Oncol 1990; 38: 367–372.CrossRefGoogle Scholar
  106. 106.
    Deligdisch L, Einstein Ai, Guera D, Gil J. Ovarian Dysplasia in Epithelial Inclusion Cysts. Cancer 1995; 76: 1027–1034.Google Scholar
  107. 107.
    Koss LG, Diagnostic Cytology and its Histopathologic Basis, 3rd ed. Philadelphia, J.B. Lippincott, 1979.Google Scholar
  108. 108.
    Polyak K, Li Y, Zhu H, Lengauer C, Wilson J.K., Markowitz S.D., Trush M.A., Kinzler K.W., and Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20: 291–293.PubMedCrossRefGoogle Scholar
  109. 109.
    Burgart L.J., Zheng J, Shu Q, Strickler J.G., Shibata D. Somatic mitochondrial mutation in gastric cancer. Am J Pathol 1995; 147: 1105–1111.PubMedGoogle Scholar
  110. 110.
    Richard S.M., Bailliet G, Paez G.L., Bianchi M.S., Peltomaki P, and Bianchi N.O. Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 2000; 60: 4231–4237.PubMedGoogle Scholar
  111. I l 1. Yeh J.J., Lunetts K.L., van Orsouw N.J., Moore F.D., Mutter G.L., Vijg J, Dahia P.L., and Eng C. Somatic mitochondria) DNA(mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000; 19: 2060–2066.PubMedCrossRefGoogle Scholar
  112. 112.
    Fliss M.S., Usadel H, Caballero O.L., Wu L, Buta M.R., Eleff S.M., Jen J, and Sidransky D. Facile detection of mitochonddrial in tumors and bodily fluids. Science 2000; 287: 2017–2019.PubMedCrossRefGoogle Scholar
  113. 113.
    Kallionemi A, Kallionemi O, Sudar D, Gray J.W., Waldman F, and Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818–821.CrossRefGoogle Scholar
  114. 114.
    Kallionemi O.P, Kallionemi A, Piper J, Isola J, Waldman F.M., Gray J.W., and Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom. Cancer 1994; 10: 231–243.CrossRefGoogle Scholar
  115. 115.
    Du Manoir S, Speicher M.R., Joos S, Schrock E., Popp S, Donner H et al. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridiization. Human Genet 1993; 90: 590–610.CrossRefGoogle Scholar
  116. 116.
    Yu LC, Moore DH 2nd, Magrane G, Cronin J, Pinkel D, Lebo RV, Gray JW. Objective aneuploidy detection for fetal and neonatal screening using comparative genomic hybridization (CGH) Cytometry 1997; 28: 191–197.PubMedGoogle Scholar
  117. 117.
    Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 214–219.Google Scholar
  118. 118.
    Pinkel D, Segraves R, Sudar D, Clark S, Poole 1, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays Nature Genetics 1998; 20: 207–11.Google Scholar
  119. 119.
    Lucito R, Nakimura M, West JA, Han Y, Chin K, Jensen K, McCombie R, Gray JW, Wigler M Genetic analysis using genomic representations Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 4487–92.Google Scholar
  120. 120.
    Moore DH 2nd, Pallavicini M, Cher ML, Gray JW A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles. Cytometry 1997; 28: 183–90.PubMedCrossRefGoogle Scholar
  121. 121.
    Thompson CT, Gray JW Cytogenic profiling using fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) (Review and 23 refs) J Cellular Biochemistry-Supplement 1993; 17G: 139–43.Google Scholar
  122. 122.
    Umayahara K, Cheneviex-Trench G, Daneshvar, L, Yang-feng, T, Collins C and Gray JW.: Molecular cytogenetic studies.“ In Ovarian Cancer 5, Sharp, F, Blackett, T, Berek, J and Bast, RC, eds., Oxford UK, ISIS Medical Media, 1998.Google Scholar
  123. 123.
    Gray JW, Chin K, Waldman F, “A Molecular cytogenetic view of chromosomal heterogeneity in solid tumors”. In Proceedings of the Eight Pezcoller Symposium: Genomic Instability and Immortality in Cancer, E Mihich and L Hartwell, eds. New York, Plenum Press, 1996.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • David A. Fishman
    • 1
  • Kenny Bozorgi
    • 1
  1. 1.Section of Gynecologic Oncology, Department of Obstetrics & GynecologyNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations